IceCure to Report First Quarter 2025 Financial & Operational Results on May 28, 2025

Rhea-AI Summary

IceCure Medical (NASDAQ: ICCM), a developer of minimally-invasive cryoablation technology for tumor treatment, has announced it will release its Q1 2025 financial and operational results on May 28, 2025, before the Nasdaq market opens. The company will host a conference call and webcast at 10:00 AM EDT on the same day to discuss the results and other corporate developments. Investors can join via US number (1-888-407-2553) or International number (+972-3-918-0696). A live webcast will be available, and a recording will be accessible on the company's investor relations website.

News Market Reaction

+0.98%

1 alert

+0.98% News Effect

On the day this news was published, ICCM gained 0.98%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

CAESAREA, Israel, May 21, 2025 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced that it will issue a press release with its financial and operational results as of and for the three months ended March 31, 2025 before the Nasdaq Stock Market opens on Wednesday, May 28, 2025. The Company will also discuss such results and other corporate developments on a conference call at 10:00 a.m. EDT on the same day.

Conference call & webcast info:
Wednesday, May 28, 2025, at 10:00 am EDT
US: 1-888-407-2553
Israel/International: +972-3-918-0696
A live webcast will be available at: https://Veidan.activetrail.biz/IcecureQ1-2025
A recording of the webcast will be available at: ir.icecure-medical.com/  

About IceCure Medical

IceCure Medical (Nasdaq: ICCM) develops and markets advanced liquid-nitrogen-based cryoablation therapy systems for the destruction of tumors (benign and cancerous) by freezing, with the primary focus areas being breast, kidney, bone and lung cancer. Its minimally invasive technology is a safe and effective alternative to hospital surgical tumor removal that is easily performed in a relatively short procedure. The Company's flagship ProSense® system is marketed and sold worldwide for the indications cleared and approved to date including in the U.S., Europe and Asia.

IR Contact:
Email: investors@icecure-medical.com
Michael Polyviou
Phone: 732-232-6914
Todd Kehrli
Phone: 310-625-4462

Logo - https://mma.prnewswire.com/media/2319310/IceCure_Medical_Logo.jpg

 

  

View original content:https://www.prnewswire.com/news-releases/icecure-to-report-first-quarter-2025-financial--operational-results-on-may-28-2025-302461786.html

SOURCE IceCure Medical

FAQ

When will IceCure Medical (ICCM) report its Q1 2025 earnings?

IceCure Medical will report its Q1 2025 financial results before the Nasdaq market opens on Wednesday, May 28, 2025.

What time is IceCure Medical's Q1 2025 earnings conference call?

IceCure Medical's Q1 2025 earnings conference call is scheduled for Wednesday, May 28, 2025, at 10:00 AM EDT.

How can investors access IceCure Medical's Q1 2025 earnings call?

Investors can access the call via US number (1-888-407-2553) or International number (+972-3-918-0696). A live webcast will also be available at Veidan.activetrail.biz/IcecureQ1-2025.

What does IceCure Medical (ICCM) do?

IceCure Medical develops minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal.